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Abstract
Objectives: Autocrine and paracrine chemokine/chemokine receptor-based interactions promote non-small-cell-lung-
cancer (NSCLC) carcinogenesis. CCL20/CCR6 interactions are involved in prostatic and colonic malignancy pathogenesis. The
expression and function of CCL20/CCR6 and its related Th-17 type immune response in NSCLC is not yet defined. We sought
to characterize the role of the CCL20/CCR6/IL-17 axis in NSCLC tumor growth.
Methods: A specialized histopathologist blindly assessed CCL20/CCR6 expression levels in 49 tissue samples of NSCLC
patients operated in our department. Results were correlated to disease progression. Colony assays, ERK signaling and
chemokine production were measured to assess cancer cell responsiveness to CCL20 and IL-17 stimulation.
Results: CCL20 was highly expressed in the majority (38/49, 77.5%) of tumor samples. Only a minority of samples (8/49,
16.5%) showed high CCR6 expression. High CCR6 expression was associated with a shorter disease-free survival (P=0.008)
and conferred a disease stage-independent 4.87-fold increased risk for disease recurrence (P=0.0076, CI 95% 1.52–15.563).
Cancerous cell colony-forming capacity was increased by CCL20 stimulation; this effect was dependent in part on ERK
phosphorylation and signaling. IL-17 expression was detected in NSCLC; IL-17 potentiated the production of CCL20 by
cancerous cells.
Conclusion: Our findings suggest that the CCL20/CCR6 axis promotes NSCLC disease progression. CCR6 is identified as a
potential new prognostic marker and the CCL20/CCR6/IL-17 axis as a potential new therapeutic target. Larger scale studies
are required to consolidate these observations.
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Introduction
Primary carcinoma of the lung is the second most frequent (12%)
cancer worldwide, and is the leading cause of cancer related death.
NSCLC (mainly lung adenocarcinoma) accounts for nearly 80% of
cases. Lung cancer is linked to a long history of smoking and to its
accompanying chronic inflammatory response [1,2,3]. Chemokines
- a familyofchemotactic cytokines,aremasterregulatorsofimmune
cell trafficking in the body [4]. Chemokines interact with seven
trans-membrane-G-protein-coupled receptors to exert their effects
[4]. Distinct immune cell subtypes express specific repertoires of
chemokine receptors, which guide their trafficking, retention and
function in target organs [5]. A variety of tumor cells express
chemokine and chemokine receptors [6]. Activation of the
chemokine\chemokine receptor axis within tumors induces auto-
crine and paracrine loops promoting tumor growth and angiogen-
esis and subverting antitumor immune response [6,7].
Distinct cytokine and chemokine/chemokine receptors charac-
terize specific types of immune responses [8]. IFN-g and CXCR3
are characteristic of Th-1-type immune response while IL-4, 5, 13
and CCR4, CCR10 are characteristic of Th-2-type immune
response [9]. Th-17-type immune response is linked to CCL20
and CCR6. Th-17 cells contribute to the eradication of
extracellular bacterial infections and also play a major role in
autoimmunity [10,11]. The involvement of Th-17 response in
malignant diseases remains unclear [12]. Ovarian cancer cells
were shown to promote the differentiation of Th-17 cells [13].
Accumulation of Th-17 cells in hepatocellular carcinoma was
linked to a worse prognosis [14].
The chemokine/chemokine receptor pair CCL20/CCR6 is a
key player in lung immunity [15]. CCL20/CCR6 is involved in
the pathogenesis of smoke-related chronic inflammatory condi-
tions such as chronic obstructive pulmonary disease and interstitial
lung fibrosis [16,17]. Activation of the CCL20/CCR6/IL-17 axis
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Klebsiella pneumoniae infection [18]. CCL20/CCR6 interactions
have recently been linked to the propagation of several
malignancies such as prostate, hepatic and pancreatic carcinomas,
raising the possibility that this axis also participates in lung
carcoinogenesis [19].
The expression, regulation and function of CCL20/CCR6/IL-
17 in NSCLC have not been characterized thus far. We sought to
characterize the role of the CCL20/CCR6/IL-17 axis in NSCLC
tumor growth.
Materials and Methods
Tissue collection and patient-specific clinical data
Fresh human lung and tumor specimens were obtained from
patients (n=20) undergoing complete resection of early stage
NSCLC (clinical stage IA-IIB) who had not received preoperative
chemotherapy or radiotherapy to exclude confounding effects.
Histological sections were prepared from these samples and an
experienced pathologist (GA) confirmed the histopathological
diagnosis. These tissues were used for the various experiments
described in this manuscript. In order to assess the correlation
between CCL20/CCR6 expression and lung adenocarcinoma
disease progression, we additionally collected 49 paraffin-embedded
tissue sections of lung adenocarcinoma tumors (clinical stage IA-IIB)
that were removed from patients in our department. The study
period was January, 2000 to September, 2010. Patients did not
receive preoperative chemotherapy or radiotherapy to exclude
confounding effects. All patients underwent an extensive sampling
of mediastinal lymph nodes. An experienced pathologist (GA)
reassessed the slides to re-confirm the diagnosis. Clinical data
(survival, time to disease recurrence and pathological staging) of these
patients was reviewed. The Hadassah Hospital Ethics Committee
approved the human component of the study. A written informed
consent was obtained from all participants involved in this research.
Assessment of CCR6 expression in lung adenocarcinoma and
correlation analysis to pathologic stage of disease were also done
using the Biomax tissue array: BC041115, which is a lung
carcinoma and normal tissue array (Biomax US. 1100 Taft St.,
Rockville, MD 20850, USA).
Immunohistochemistry of CCL20 and CCR6
Antigen retrieval was performed in EDTA buffer for 20 minutes
in microwave. Sections were stained with the anti-human CCR6
Figure 1. Expression of CCR6/CCL20 in NSCLC tissue samples. PCR signal for CCL20, CCR6 and beta-actin in three NSCLC tumor samples (A).
CCL20 protein levels in NSCLC tumors and in tumor adjacent lung tissue (n=3) (B). Representative immunohistochemistry staining for CCL20 and
CCR6 in lung adenocarcinoma tissue sections. CCL20 - Low X10 (D) and high power X20 (E) magnification. CCR6 - Low power (X10) (F, G) and high
power (X20) (H) magnification. Immune cell infiltrates located with in lung adenocarcinoma tumor stain positive for CCR6 (X40) (I). Negative control
staining (X10) is shown (C). (*P,0.05)
doi:10.1371/journal.pone.0024856.g001
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USA) - concentration 10 mg/ml, or with anti-human CCL20
polyclonal antibody (PeproTech EC, London, UK), - concentra-
tion of 20 mg/ml. Next, the sections stained for CCL20 were
incubated with diluted 1:1000 biotinylated goat-antirabbit anti-
body (Jackson ImmunoResearch), for 30 minutes and thereafter
with horseradish peroxidase - conjugated streptavidin (Zymed
Laboratories, San Francisco, CA,USA) for 30 minutes. The
sections stained for CCR6 or CCL20 were incubated with
secondary anti-mouse horseradish peroxidase-conjugated antibody
(DakoCytomation, Glostrup, Denmark) for 30 minutes at room
temperature. 3-amino-9-ethylcarbazole (AEC) was used for color
development, and sections were counterstained with hematoxylin.
Negative control sections were stained with either no primary
antibody (PBS) or with isotype-matched control antibody.
Histological evaluation of CCL20/CCR6 staining
Two experienced pathologists blindly assessed tissue sections for
the percentage of tumor cells staining positive for CCL20 and
CCR6. Samples were divided into four categories: 1. 0–25% of
tumor cells stained positive, 2. 25–50% of tumor cells stained
positive, 3. 50–75% of tumor cells stained positive, 4. 75–100% of
tumor cells stained positive. High expression of the chemokine or
receptor was defined if more than 50% of tumor cells stained
positive.
Analysis of the Biomax lung cancer tissue array was done as
follows: CCR6 staining intensity was scored from 0 to 3 (0 – no
staining, 1 – week intensity, 2 – medium intensity and 3 – high
intensity); the percentage of CCR6 positive cells (four categories as
described above) was also scored. For each sample, we calculated a
CCR6 staining index: CCR6 index = (CCR6 Staining intensity *
Percentage of CCR6 positive tumor cells)/100.
ELISA assays of CCL20 and IL-17
Tumor and lung tissue homogenates were prepared on ice from
weighed tissue samples. CCL20 levels in these homogenates were
measured. Levels of CCL20 in the supernatant of NSCLC-derived
cell lines (L3, L4 and L549) were measured in the presence or
absence of IL-17 (25, 100, 1,000 ng/ml). IL-17 levels were
measured in the supernatant of tumor-derived immune cells and in
the supernatant of lung-derived immune cells in the presence or
absence of anti OKT3 antibody. ELISA assays were performed
with Quantikine kits according to the manufacturer’s instructions
(R&D Systems, Inc., Minneapolis, MN 55413, USA).
Isolation of normal lung- and tumor tissue-derived
lymphocytes
Isolation of normal lung- and tumor tissue-derived lymphocytes
was done as previously described [20]. For activation experiments,
2*10
5 cells were plated in each well in the presence or absence of
(10 microgram/ml) anti CD3 antibody clone OKT3 (eBioscience);
supernatant was collected after 5 days.
NSCLC cell lines
The A549 – cell line was purchased from the ATCC (Rockville,
MD, USA). Two primary NSCLC cell lines were generated in our
laboratory as previously described; the L3 line was generated from
lung adenocarcinoma and the L4 line from large cell carcinoma
[21]. All cell lines were tested for mycoplasma contamination and
were found to be negative.
Fingerprinting and Tissue genotyping
In order to ascertain that our NSCLC-derived cell lines, L3 and
L4, differ from each other and from the A549 ATCC cell line, we
performed fingerprinting of these cells as described by Silva et al.
[22]. We also performed tissue genotyping with the Applied
Biosystems AmpFlSTR Identifiler plus kit, according to the
manufacturer’s protocol. The fingerprinting data are provided as
supplementary material (Figure S1).
Flow cytometry analysis of neoplastic cells
We performed flow cytometry analysis of 1.5X10
5/ml of
primary tumor-derived neoplastic cells (L3 and L4) and the
NSCLC cell line A549. Cells were blocked with 1% human
plasma for 15 minutes and then mixed with PE - conjugated anti-
Table 1. Patient’s characteristics.
N= 49
Age 65.8 +/2 8.91
Gender 25 female/24 male
Stage I 32
Stage II 9
Stage III 8
Follow up
Mean 54 +/2 23.5 months
Median 52 months
Range 18–125 months
doi:10.1371/journal.pone.0024856.t001
Table 2. For CCL20, indicates the number of slides that were
allocated to each staining category according to disease
stage.
CCL20 0–25% 25–50% 50–75% 75–100%
Stage I 6 2 5 19
Stage II 1 0 2 6
Stage III 2 0 2 4
Total 9 2 9 29
Samples were divided into four categories according to percent of tumor cells
staining positive: 1. 0–25% of tumor cells stained positive, 2. 25–50% of tumor
cells stained positive, 3. 50–75% of tumor cells stained positive, 4. 75–100% of
tumor cells stained positive.
doi:10.1371/journal.pone.0024856.t002
Table 3. For CCR6, indicates the number of slides that were
allocated to each staining category according to disease
stage.
CCR6 0–25% 25–50% 50–75% 75–100%
Stage I 19 7 3 3
Stage II 9 0 0 0
Stage III 6 0 0 2
Total 34 7 3 5
Samples were divided into four categories according to percent of tumor cells
staining positive: 1. 0–25% of tumor cells stained positive, 2. 25–50% of tumor
cells stained positive, 3. 50–75% of tumor cells stained positive, 4. 75–100% of
tumor cells stained positive.
doi:10.1371/journal.pone.0024856.t003
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anti-CCR6 antibody, clone 53103.11 (R&D Systems, Inc.,
Minneapolis, MN 55413, USA) or with isotype control for 20.
For CCL20 staining cells, the fixation and permeabilization
method was performed prior to incubation with the antibody.
Immunostained cells were analyzed by flow cytometry using the
FACS Caliber Flow Cytometer (Becton Dickinson, Mountain
View, CA, USA). Data were analyzed using the CellQuest
software. (Version 3.3, Becton Dickinson).
We used the anti-CCR6 antibody clone 53103.11 in both flow
cytometry and immunohistochemistry staining. To demonstrate
the specificity of this clone for CCR6, we incubated fresh PBMC
in the presence or absence of 20 ug/ml CCL20 for one hour and
stained the cells for CCR6 or with isotype control antibody.
Reduced CCR6 staining was observed in CCL20 treated cells;
results are provided as supplementary material (Figure S2).
Western blot of ERK and p-ERK
Western blot analysis of ERK and phosphorylated ERK was
carried out as previously described and according to the
manufacturer’s recommendation [23]. In short, cells were
stimulated with 500 ng/ml of CCL20 (R&D Systems Minneapolis,
MN 55413, USA), and harvested at 0, 5, 15, 30 and 60 minutes.
ERK and pERK detection was done (rabbit polyclonal antibodies
specific for p-ERK, ERK - Santa Cruz, CA, USA) following the
manufacturer’s recommendations. Goat anti-rabbit horseradish
peroxidase–conjugated antibodies were then used. Bands were
scanned by a densitometer ImageMaster VDS-CL machine,
(Pharmacia Biotech, Piscataway, NJ, USA).
Colony assays
Agar base layer was prepared as follows: 45 ml of RPMI +12%
FCS was mixed with 15 ml of RPMI X2 + 12% FCS and with
15 ml of 2.5% agar in double distilled water. Tumor cells were
suspended in RPMI + 10% FCS. Cell suspension was mixed in a
ratio of 1:3 with the agar base solution. This mixture was then
plated on top of a preformed solid agar base. CCL20, at the
concentrations of 10 ng/ml, 50 ng/ml and 250 ng/ml, and the
ERK inhibitor PD98059 at the concentration of 20 microliter/ml,
were added to the mixture. Fourteen days later, the number of
colonies was counted in ten different fields.
PCR
The following primers were used:
CCL20 – sense ATGTGCTGTACCAAGAGTTT, antisense
CAAGTCTGTTTTGGATTTGC.
CCR6 – sense CCATTCTGGGCAGTGAGTCA, antisense –
AGCAGCATCCCGCAGTTAA
Figure 2. CCR6/CCL20 expression and NSCLC disease progression. Kaplan-Meier analysis of disease free survival interval (months) according
to disease stage. (A). Kaplan-Meier analysis of disease free survival interval (months) according to percentage of CCR6 positive cells. (B). CCR6 staining
index for lung adenocarcinoma and squamous cell carcinoma according to disease stage is shown (C).
doi:10.1371/journal.pone.0024856.g002
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GGCACTTTGCCTCCCAGAT
IL-17A receptor – sense GCGCCCAGACCAGAAGAG,
antisense – CCCTTTAAGGTTGCGTAGAGTGA
b-actin – sense CCCTGGACTTCGAGCAAGAG, antisense –
TCTCCTTCTGCATCCTGTCG
Statistical Analysis
Data are expressed as mean 6 standard error (SE) and as
absolute values. Continuous data with normal distribution were
analyzed using t-test. Time to disease recurrence was estimated
non-parametrically by the Kaplan-Meier method. Cox regression
analysis was performed to define the relevance of high CCR6
expression as a disease stage independent marker for disease
recurrence. A p value of 0.05 was considered significant. Statistical
analyses were performed using the SPSS software (IBM).
Results
Expression of CCR6/CCL20 in NSCLC tissue samples
The expression of CCL20 and CCR6 in fresh NSCLC samples
was assessed by PCR and ELISA assays. Figure 1A depicts three
representative tumor samples, documenting PCR signal for the
ligand and its receptor. CCL20 protein levels in NSCLC tumors
were significantly higher as compared to the levels of the protein in
tumor adjacent normal lung tissue (Figure 1B).
Using immunohistochemistry, we defined the expression
patterns of CCL20 and CCR6 in lung adenocarcinoma. Low
X10 and high power X20 magnification of CCL20 staining is
shown in Figure 1D and Figure 1E. Tumor tissue stained positive
for CCL20 while tumor adjacent lung tissue was negative. Three
samples of tumor sections stained for CCR6 are shown: in
Figure 1F (X10), no CCR6 staining was observed. Figure 1G
(X10) represents low to medium expression of CCR6 by tumor
cells and Figure 1H (X20) demonstrates high CCR6 expression;
in these samples, some of the tumor cell nuclei also stained
positive for CCR6. Immune cell infiltrates located within lung
adenocarcinoma tumor stained positive for CCR6 (X40)
(Figure 1I). Negative control staining (X10) is shown in
Figure 1C.
CCR6/CCL20 expression and NSCLC disease progression
To study the clinical relevance of CCL20/CCR6 expression in
NSCLC, we tested the expression of the chemokine and receptor
in 49 lung adenocarcinoma tissue samples removed during
surgery. Results were correlated with patient pathological stage
Figure 3. Expression of CCR6/CCL20 in NSCLC-derived cell lines. PCR signal for CCL20, CCR6 and beta-actin in L3, L4 and A549 cell lines (A).
ELISA assay for CCL20 in the supernatant of L3, L4 and A549 cell lines (B). Flow Cytometry histogram analysis of CCR6 and CCL20 staining of L3, L4 and
A549 cell lines, control antibody – purple, staining antibody – green line (C).
doi:10.1371/journal.pone.0024856.g003
CCR6/CCL20/IL-17 Axis in NSCLC
PLoS ONE | www.plosone.org 5 September 2011 | Volume 6 | Issue 9 | e24856of disease and with time of disease recurrence. Patients’
characteristics are shown in Table 1. Table 2 (for CCL20) and
Table 3 (for CCR6) show the number of slides that were allocated
to each staining category according to disease stage. The majority
of tumor samples (38/49 (78%)) showed high (.50%) expression
of CCL20. Oppositely, a minority of tumor samples (8/49 (16%))
expressed high (.50%) levels of CCR6. As expected, the Kaplan-
Meier analysis indicated that a more advanced disease stage is
associated with a shorter disease free survival (P,0.0001)
(Figure 2A). Using the same method, we found that high CCR6
expression is associated with a shorter disease free survival
(P=0.008). COX regression analysis identified high CCR6
expression as a disease-stage independent marker for disease
recurrence. High CCR6 expression conferred a 4.87-fold
increased risk for disease recurrence (P=0.0076, CI 95% 1.52–
15.563) (Figure 2B).
CCR6 expression and NSCLC disease stage
To examine the correlation between CCR6 expression and
NSCLC disease stage, we measured CCR6 staining index in a
tumor tissue array enclosing lung adenocarcinoma samples
homogenously spread among the different disease stages. The array
included 52 samples of lung adenocarcinoma (19 samples of stage I
disease, 16 samples of stage II disease,16 samplesof stage III disease
and 1 sample of stage IV disease) and 41 samples of squamous cell
carcinoma (20 samples of stage I disease, 6 samples of stage II
disease and 17 samples of stage III disease). The average CCR6
staining index was 0.75 +/2 0.16 for stage I adenocarcinoma, 1.05
+/2 0.24 for stage II adenocarcinoma and 1.37 +/2 0.22 for stage
III adenocarcinoma. The increased CCR6 staining index observed
in stage III relative to stage I adenocarcinoma was statistically
significant P=0.03 (Figure 2C). The average staining indices for
squamous cell carcinoma were 1.44 +/2 0.19, 1.2 +/2 0.34 and
Figure 4. CCL20 induces NSCLC proliferation and ERK phosphorylation. Colony formation by L3, L4 and A549 cells in response to
stimulation with increasing concentrations of CCL20 (A, B, C). ERK phosphorylation in L3, L4 and A549 cells in response to CCL20 stimulation.
Phosphorylated ERK upper panel and total ERK lower panel (D, E, F). (*P,0.05, **P,0.01)
doi:10.1371/journal.pone.0024856.g004
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statistical difference was found among this group (Figure 2C).
Expression of CCR6/CCL20 in NSCLC-derived cell lines
We characterized the expression of CCL20/CCR6 in three
NSCLC-derived cell lines (L3, L4 and A549). A low level of CCR6
expression was detected in all three-cell lines (Figure 3A PCR and
3C flow cytometry). Differential expression and production of
CCL20 by the three cell lines was detected (Figure 3A PCR, 3B
ELISA and 3C Flow cytometry).
CCL20 induces NSCLC proliferation and ERK
phosphorylation
The effect of CCL20 stimulation on neoplastic cell proliferation
was studied using colony assays. Stimulation of L3, L4 and A549
cells by increasing concentrations of CCL20 promoted colony
formation in a dose-dependent fashion (Figure 4A, B, C). CCL20
stimulation of L3, L4 and A549 cells induced ERK phosphory-
lation 5, 15 and 30 minutes after exposure (Figure 4D, E and F
upper panel) with no change in total ERK levels (lower panel).
Inhibition of phospho-ERK signaling by the specific inhibitor
PD98059 did not affect the basal colony formation capacity of
these cells (Figure 5A, B, C); however, it significantly decreased the
potential of CCL20 to induce colony formation by L4 and A549
cells (Figure 5B, C).
IL-17 is expressed in NSCLC and induces CCL20
production by NSCLC-derived cell lines
The expression of IL-17A and IL-17A receptor in NSCLC
tissue samples in tumor adjacent lung tissue and in L3, L4 and
A549 cell lines was tested. PCR signal for IL-17A was low in two
samples and negative in an additional two samples of tumor
adjacent lung tissue (Figure 6A). Two out of four tumor samples
showed high signal for IL-17A and one showed a weak signal
(Figure 6B). The IL-17A signal was negative in all cancerous cell
lines (Figure 6C). The IL-17A receptor was highly expressed by
tumor samples and tumor cell lines (Figure 6B, C). In two cases,
infiltrating immune cells were isolated from tumor tissue and
tumor adjacent lung tissue; these cells were incubated with or
without anti CD3 antibody (OKT3) and the production of IL-17
was assessed by ELISA. Activated tumor-derived immune cells
produced higher levels of IL-17 (Figure 6D, E). The effects of IL-
17 and IL-22 stimulation on CCL20 production by neoplastic cells
were studied. Semi-quantitative PCR analysis showed that IL-17,
Figure 5. ERK inhibition decreases CCL20-mediated NSCLC proliferation. Colony formation by L3, L4 and A549 cells in response to
stimulation with increasing concentrations of CCL20 in the presence or absence of the ERK inhibitor PD98059 (A, B, C).
doi:10.1371/journal.pone.0024856.g005
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mRNA in L3 and L4 cells and to a lesser extent in A549 cells
(Figure 6F, G, H). ELISA assays showed a dose-dependent
increase in CCL20 production following IL-17 stimulation
(Figure 6I, J, K).
Discussion
Chemokine receptor expression by tumor cells enhances their
survival, proliferation and metastatic potential. Both tumor cells
and tumor stroma produce chemokines [8]. Several groups
examined the role of the chemokine/chemokine receptor pair,
CCL20/CCR6, in malignancy. Pirus Ghadjar et al., have shown
that CCR6 expression guide hepatic metastasis of colonic
malignancies [24]. Kimsey et al., reported that co-localization of
CCL20 and CCR6 promotes pancreatic cancer cell invasion [25].
Others and we have shown that CCL20/CCR6 auto-signaling
occurs in prostatic cancerous cells and that tumor CCR6
expression correlates with disease aggressiveness [7,26], thus
marking intra-tumoral CCL20/CCR6 interactions as a pro-
carcinogenic axis. CCL20 is over-expressed by lung epithelial
cells in response to smoke and particulate matter [27]. The role of
this chemokine in lung cancer pathogenesis has not been studied
thus far. To test the potential pro-carcinogenic effects of CCL20
and CCR6 in lung cancer, we first aimed to characterize the
expression and tissue localization of this chemokine/chemokine
receptor pair in NSCLC tumors. Immunohistochemistry studies
indicated that the majority of lung adenocarcinoma tumor samples
highly stained for CCL20, while only a minority highly expressed
CCR6. Using Kaplan-Meier analysis, we looked for associations
between the clinical course of lung adenocarcinoma patients and
the extent of CCL20/CCR6 staining in their tumor samples. We
found that high CCR6 expression was associated with a shorter
disease-free survival (P=0.008). Furthermore, Cox regression
analyses showed that high CCR6 expression was associated with a
4.87-fold increased risk for disease recurrence (P=0.0076, CI 95%
1.52–15.563) and the effect of CCR6 was independent of
pathological stage of disease. The strength of this study lies on
focusing on an accurate pathological staging, a specific diagnosis
(lung adenocarcinoma) and the long duration of clinical follow-up.
The weakness of this study is its relatively small sample size (49
patients). In order to expand the sampled data, we performed an
Figure 6. IL-17 is expressed in NSCLC and induces CCL20 production by NSCLC-derived cell lines. PCR signal for IL-17A, IL-17A receptor
and b-actin in NSCLC tissue samples, in tumor adjacent lung tissue and in L3, L4 and A549 cell lines. Tumor adjacent lung tissue (A). NSCLC tumor
sample (B). L3, L4 and A549 cell lines (C). Infiltrating immune cells were isolated from tumor tissue (TD-IC) and tumor adjacent lung tissue (LD-IC).
Immune cells were incubated with or without anti CD3 antibody and production of IL-17 assessed by ELISA - two cases (D, E). Semi-quantitative PCR
analysis for CCL20 in L3, L4 cells 549 cells in response to IL-17 and IL-22 stimulation (F, G, H). ELISA assays for CCL20 in the supernatant of L3, L4 cells
549 cells following stimulation with increasing concentrations of IL-17 (I, J, K).
doi:10.1371/journal.pone.0024856.g006
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enclosing over 50 lung-adenocarcinoma samples homogenously
spread among the different disease stages. In this array, we found a
higher CCR6 staining index among advanced stage adenocarci-
nomas. This pattern was unique for adenocarcinoma, albeit not
detected in squamous cell tumors. Shedden K. et al., have
extensively examined the gene expression-based survival of lung
adenocarcinoma patients [28]. Their data, containing clinical
parameters and gene profiling of over 400 samples from lung
adenocarcinoma patients, is available for download from the
NCBI. We examined the expression patterns of CCL20 and
CCR6 in this database. The reported gene array signal detection
was low for CCR6, ranging between 4 to 115 and high for
CCL20, ranging from 2–5,597. In contrast to the immunohisto-
chemistry results described above we have not found a correlation
between CCR6 gene array signal intensities and lung adenocar-
cinoma disease parameters. The different methods of detection,
degradation of CCR6 mRNA and reduced sensitivity of the
specific probe for CCR6 may account for this discrepancy.
Interestingly however, we have found highly significant correla-
tions between CCL20 signal intensities and three clinical
parameters: 1) Vital status of patients (Alive – 535+/258 vs.
dead – 786 +/2 72, P=0.008), 2) Tumor differentiation (Well
differentiated – 334+/283 vs. poorly differentiated – 793 +/2 88,
P=0.004) and 3) T score of TNM staging system (T-1 – 552+/
268 vs. T-3/4 – 1055 +/2 207, P=0.005). Take together, this
data suggest that CCL20/CCR6 interactions in the tumor
microenvironment may stimulate NSCLC disease progression.
CCR6 is identified as a potential disease marker. These
observations add to the accumulating clinical data regarding the
involvement of CCL20/CCR6 in malignancy and mark this axis
as a potential therapeutic target.
To test in vitro the potential effects of CCL20/CCR6
interactions in NSCLC, three tumor cell lines were tested. L3,
L4 and A549 cells expressed low levels of CCR6 and produced
varying levels of CCL20. Stimulation of these lines with CCL20
induced colony formation in a dose-dependent manner. CCR6-
dependent ERK phosphorylation mediated proliferation of
colorectal cancer cells [29]. Activation of ERK signaling was also
considered as a key pathway in NSCLC development [30]. We
found that CCL20 induced ERK phosphorylation in L3, L4 and
A549 cells. Furthermore, inhibition of ERK signaling by PD98059
decreased the potential of CCL20 to induce colony formation
while it did not affect the basal numbers of colonies formed, thus
demonstrating the pro-proliferative potential of CCL20/CCR6
auto-signaling in NSCLC and marking ERK as an intracellular
mediator of these signals.
Autocrine and paracrine chemokines/chemokine receptor
interactions link chronic inflammation to malignancy [31].
CCL20 is a bi-functional peptide with both innate and adaptive
immune properties. CCL20 is induced in human airway epithelia
by various pro-inflammatory signals as well as by smoke and
particulate matter [15,32]. CCL20 is the only chemokine known
to interact with the receptor CCR6 [32]. CCL20 promotes smoke-
related lung inflammation by the recruitment of CCR6-expressing
subset of immune cells into lung parenchyma [16,17]. For
example, chronic cigarette smoke exposure induced the accumu-
lation of CD4+ CCR6+ Th17-type in mouse airways resulting in
airspace enlargement [33,34]. Numasaki et al. reported that
NSCLC tumors contain infiltrates of CD3+ IL-17 expressing cells
and suggested that the crosstalk among these cells and the
neoplastic cells enhances local tumor progression [35]. The
trafficking of Th-17 cells is guided by CCR6 [36]. Here we show
that intra-tumoral levels of CCL20 were elevated as compared to
tumor adjacent lung tissue and that CCR6 positive immune cell
infiltrates were found in the tumor parenchyma. PCR signal for
IL-17 was detected in three out of four NSCLC tissue samples,
however it was not found in any of the tumor cell lines and was
only weakly expressed in two out of four tumor adjacent lung
tissue samples. Activation of tumor infiltrating immune cells with
anti CD3 antibody induced IL-17 production. In line with
previous reports, these observations suggested that IL-17 produc-
ing cells infiltrate NSCLC tumors. All NSCLC tumors and cell
lines expressed the IL-17 receptor. We found that stimulation of
NSCLC cell lines with IL-17- induced CCL20 production in a
dose-dependent manner. Immature dendritic cells, FoxP3 regula-
tory T cells and Th-17 cells all expressed CCR6 and were reported
to accumulate in NSCLC tumors [20,36,37]. We speculate that
IL-17-induced CCL20 production in the tumor microenvironment
may act in an autocrine manner to stimulate tumor cell growth
and in a paracrine manner to enhance the tumor-associated
inflammatory response.
In conclusion, our findings suggest that the CCL20/CCR6 axis
promotes NSCLC disease progression. CCR6 is identified as a
potential new prognostic marker and the CCL20/CCR6/IL-17
axis as a potential new therapeutic target. Larger scale studies are
required to consolidate these observations.
Supporting Information
Figure S1 Fingerprinting according to reference 22.
(TIFF)
Figure S2 To demonstrate the specificity of anti-CCR6
clone 53103.11 we incubated fresh PBMC in the presence
or absence of 20ug/ml CCL20 for one hour and stained
the cells for CCR6 or with isotype control antibody.
Reduced CCR6 staining was observed in CCL20 treated cells.
Grey - control antibody, Red - no CCL20 treatment, Black -
CCL20 treatment.
(TIFF)
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